Philips and Infraredx sign agreement for the resale of Infraredx's TVC Imaging System integrated with Philips' interventional X

Philips and Infraredx sign agreement for the resale of Infraredx's TVC Imaging
         System integrated with Philips' interventional X-ray systems

Agreement expands Philips' interventional cardiology portfolio

Collaboration enhances Infraredx's global commercialization strategy and
expands access to Philips' customers in North America and Europe

PR Newswire

ANDOVER AND BURLINGTON, Mass., Oct. 28, 2013

ANDOVER AND BURLINGTON, Mass., Oct. 28, 2013 /PRNewswire/ -- Royal Philips
(NYSE: PHG; AEX: PHIA) and  Infraredx, Inc., a medical device company
committed to advancing the diagnosis and management of coronary artery disease
today announced a non-exclusive resale agreement for Infraredx's TVC Imaging
System. Under the terms of the agreement, Philips will sell Infraredx's TVC
Imaging System alongside its Allura interventional X-ray systems in North
America and Europe, expanding its interventional cardiology portfolio of
advanced live image guidance solutions, clinical informatics and
interventional tools.

Philips Cath Lab.

Coronary artery disease (CAD) is caused when plaque builds up along the inner
walls of the coronary (heart) arteries, causing them to narrow and reduce
blood flow to the heart muscle. It can be treated with percutaneous coronary
intervention (PCI), a catheter-based procedure that is performed in a cath lab
under interventional X-ray guidance. Increasingly, additional catheter-based
intravascular imaging technologies, such as the TVC Imaging System, are being
used to assess the structure and composition of plaques from within the blood
vessel, and to guide the interventional treatment for better procedural

The TVC Imaging System is a first-in-class intravascular imaging system that
integrates near-infrared spectroscopy (NIRS) lipid core plaque (LCP) detection
technology, and enhanced intravascular ultrasound (IVUS) imaging to visualize
the presence of plaques, quantify the degree of vessel stenosis (narrowing)
and identify plaques prone to rupturing and causing dangerous blockages.

"Our goal is to further improve existing image-guided interventions and
therapies and to enable new ones," said Ronald Tabaksblat, general manager,
interventional X-ray at Philips Healthcare. "By teaming up with Infraredx to
sell the TVC Imaging System, our product portfolio will be enhanced with an
innovative intravascular imaging technology that works seamlessly with our
interventional X-ray systems for better-informed treatment decisions and
real-time therapy monitoring."

"We're pleased to partner with Philips, the leader in interventional X-ray
systems, to expand access to our innovative TVC Imaging System among Philips'
broad and established customer base in North America and Europe," said Don
Southard, president and chief executive officer of Infraredx. "This resale
agreement advances our global commercialization strategy by increasing our
product's penetration in the cardiac imaging market."

In March of this year, Infraredx and Philips already launched a software
solution to enable the integration of the TVC imaging system with Philips'
Allura Xper and AlluraClarity interventional X-ray systems. The software
enables an easy and quick setup of the TVC imaging system in conjunction with
Philips' Allura systems, and it allows clinicians tableside control of the TVC
Imaging System using the Allura system controls.

Clinicians can view a TVC composite image, which shows both the near infrared
spectroscopy image and the IVUS image, alongside the coronary angiogram (a
contrast-enhanced X-ray image of the coronary arteries) on the Philips Allura
monitors. The TVC composite image allows for better visualization of lipid
core plaques, which are known to cause complications in PCI procedures and
suspected of being the principal cause of most heart attacks.

As a global leader in interventional cardiology, Philips offers a
comprehensive portfolio of solutions. Philips' AlluraClarity interventional
X-ray system with its powerful ClarityIQ technology provides high quality
imaging for a comprehensive range of clinical procedures, achieving excellent
visibility at low X-ray dose levels for patients of all sizes. AlluraClarity's
low X-ray dose settings help clinicians to better manage their patients' and
their own exposure to X-ray radiation.

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being
company, focused on improving people's lives through meaningful innovation in
the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the
Netherlands, Philips posted 2012 sales of EUR 24.8 billion and employs
approximately 114,000 employees with sales and services in more than 100
countries. The company is a leader in cardiac care, acute care and home
healthcare, energy efficient lighting solutions and new lighting applications,
as well as male shaving and grooming and oral healthcare. News from Philips is
located at

About Infraredx, Inc.
Infraredx, Inc. is a privately-funded medical device company dedicated to
helping provide practitioners with the information needed for enhanced
clinical decision making in treating coronary artery disease. The company is
committed to improving the safety and efficacy of coronary stenting and
ultimately serving as part of a strategy to prevent initial coronary events.

Through its TVC Imaging System™, Infraredx is changing the way coronary artery
disease is diagnosed and treated. The TVC Imaging System is the only
intravascular imaging system that enables true vessel characterization through
simultaneous structural and compositional imaging data obtained in a single
pullback. Founded in 1998, Infraredx is headquartered in Burlington, Mass. For
more information, visit

About The TVC Imaging System™
The TVC Imaging System™ is a first-in-class intravascular imaging system that
holds the potential to revolutionize the management of coronary artery disease
by providing information that is critical for evaluating vessel structure and
composition, also known as true vessel characterization. The TVC Imaging
System helps interventional cardiologists identify which patients are prone to
complications during stenting. The device enables cardiologists to predict
peri-procedural heart attacks by assessing not only the degree of stenosis,
but also the presence and extent of lipid-rich plaques (LRP).

The device is the only multimodality imaging system to combine both
intravascular ultrasound (IVUS) and near-infrared spectroscopy (NIRS). Through
IVUS technology, the TVC Imaging System provides clear and relevant
information about vessel structure, in real time. The TVC Imaging System is
the only device available in both the U.S. and Europe for the detection of
LCPs. NIRS measurements have been made in over 5,000 patients in over 100
hospitals worldwide.

TVC Imaging System Catheter.

TVC Imaging System Catheter.

TVC Imaging System Composite.

Rachel Bloom-Baglin
Philips Healthcare
Tel: +1 978- 659-3748

Steve Klink
Philips Group Communications
Tel: +31 6 1088 8824

Vice President of Marketing, Infraredx, Inc.
Tel: +1

Susan Heins
Pure Communications, Inc. for Infraredx, Inc.
Tel: +1

Related Links

Image with caption: "Philips Cath Lab." Image available at:

Image with caption: "TVC Imaging System Catheter." Image available at:

Image with caption: "TVC Imaging System Catheter." Image available at:

Image with caption: "TVC Imaging System Composite." Image available at:

SOURCE Royal Philips

Press spacebar to pause and continue. Press esc to stop.